The stock of InflaRx N.V (NASDAQ: IFRX) has increased by 11.35 when compared to last closing price of 2.29.Despite this, the company has seen a loss of -3.41% in its stock price over the last five trading days. globenewswire.com reported 2024-12-20 that JENA, Germany, Dec. 20, 2024 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that the first patient has been dosed in its Phase 2a basket study in chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), investigating the Company’s oral C5aR inhibitor, INF904.
Is It Worth Investing in InflaRx N.V (NASDAQ: IFRX) Right Now?
Additionally, the 36-month beta value for IFRX is 1.64. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for IFRX is 48.83M and currently, short sellers hold a 0.44% ratio of that float. The average trading volume of IFRX on January 08, 2025 was 265.79K shares.
IFRX’s Market Performance
IFRX stock saw an increase of -3.41% in the past week, with a monthly gain of 3.66% and a quarterly increase of 66.67%. The volatility ratio for the week is 11.23%, and the volatility levels for the last 30 days are 10.29% for InflaRx N.V (IFRX). The simple moving average for the past 20 days is 5.42% for IFRX’s stock, with a 54.39% simple moving average for the past 200 days.
Analysts’ Opinion of IFRX
Many brokerage firms have already submitted their reports for IFRX stocks, with Guggenheim repeating the rating for IFRX by listing it as a “Buy.” The predicted price for IFRX in the upcoming period, according to Guggenheim is $8 based on the research report published on April 05, 2023 of the previous year 2023.
Raymond James gave a rating of “Strong Buy” to IFRX, setting the target price at $14 in the report published on October 28th of the previous year.
IFRX Trading at 20.98% from the 50-Day Moving Average
After a stumble in the market that brought IFRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.41% of loss for the given period.
Volatility was left at 10.29%, however, over the last 30 days, the volatility rate increased by 11.23%, as shares sank -2.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +59.37% upper at present.
During the last 5 trading sessions, IFRX fell by -3.41%, which changed the moving average for the period of 200-days by +65.58% in comparison to the 20-day moving average, which settled at $2.42. In addition, InflaRx N.V saw 3.24% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for IFRX
Current profitability levels for the company are sitting at:
- -332.67 for the present operating margin
- -3.94 for the gross margin
The net margin for InflaRx N.V stands at -335.19. The total capital return value is set at -0.85. Equity return is now at value -62.38, with -54.58 for asset returns.
Currently, EBITDA for the company is -44.81 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 709.78. The receivables turnover for the company is 0.07for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.31.
Conclusion
In conclusion, InflaRx N.V (IFRX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
